Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients

Core Insights - Annovis Bio Inc. (NYSE:ANVS) is experiencing a significant increase in stock price, trading up 55.91% at $3.65, with a session volume of 12.29 million compared to an average volume of 615.12 thousand [1][4] Group 1: Clinical Data and Efficacy - The company’s late-stage clinical drug platform focuses on neurodegenerative diseases, particularly Alzheimer's and Parkinson's disease, and has revealed new data on the impact of amyloid co-pathology on cognitive outcomes in Parkinson's patients [1] - In a Phase 3 study involving early Parkinson's disease patients, the drug buntanetap halted cognitive decline across the overall patient population, with the most significant improvements noted in patients with mild dementia [2] - Approximately 25% of patients in the study exhibited amyloid co-pathology, which correlated with more pronounced cognitive decline; however, this decline was counteracted and reversed by treatment with buntanetap [2] Group 2: Mechanism and Biomarkers - The findings support Annovis's principle that neurodegenerative diseases often involve multiple neurotoxic proteins, which contribute to cognitive and functional decline [3] - Treatment with buntanetap resulted in significant cognitive improvements in Parkinson's patients with amyloid co-pathology, further validated by measurable reductions in biomarkers such as pTau217, total tau, and brain-derived tau, which are established indicators of neurodegeneration in Alzheimer's disease [3]